At the news
? BULLISHIMPACT 5/10 8-K filed Aug 13, 2026 at 07:30 ET
Collegium Pharmaceutical announced an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock, as part of a previously authorized $150 million buyback program. The company will receive an initial delivery of ~1.56 million shares (80% of expected total) based on the $25.70 closing price, with final settlement by Q4 2026. This signals management's confidence in the company's valuation and capital allocation, though it does not provide new information on underlying business fundamentals.
- Collegium entered an accelerated share repurchase (ASR) agreement with Jefferies LLC to repurchase $50 million of its common stock.
- The ASR is part of a $150 million share repurchase program authorized by the Board in July 2025.
- Initial delivery of 1,556,420 shares based on the $25.70 closing price on August 12, 2026, representing ~80% of expected total repurchase.
- Final settlement expected no later than Q4 2026; as of June 30, 2026, Collegium had ~32.5 million shares outstanding.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access